New startup ideas · Consumer and commerce · Consumer
startup idea
Talvia
FDA-cleared autonomous AI therapy, sold to health plans at one-tenth the cost.
Talvia builds a clinically validated conversational AI that delivers protocolized CBT for anxiety and depression as a covered insurance benefit, replacing 150-dollar-per-session human therapy with a 15-dollar-per-member-per-month product.
- Software subscription
- Enterprise
- $10-100B market
- Collapses a cost 10x
- US first
5/5
venture judge
15
similar startups, last 2 years (67 all-time)
92%
of 2 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$2,500 · 6 weeks · 15 prospects
For $2,500 in 6 weeks, prove that a regional health plan will sign a dated pivotal-trial partnership with coverage terms at $15 per member per month for autonomous AI therapy, before any code or trial exists.
Riskiest assumption · A regional health plan's medical director will commit the plan's name, members, and a dated start to autonomous AI therapy with no human clinician in the loop - because if no payer will sign before clearance, none of the liability, pricing, or category-freeze objections gets cheaper after three years of trials.
1Focus group: who and where
The behavioral health medical director or VP of behavioral health at a regional nonprofit health plan with 100,000 to 2 million members, currently failing network-adequacy standards on anxiety and depression referrals and paying around $150 per human therapy session.
where to find 15 · The Alliance of Community Health Plans member directory, roughly 30 regional nonprofit plans with named clinical leadership (list); the Behavioral Health Tech 2026 conference, where payer behavioral health teams attend (event); warm introductions through two or three benefits consultants and digital-health advisors who already sell into these plans (channel); AHIP's payer membership as a secondary list.
2Sell first, build later
A pivotal-trial partnership: the plan supplies members with moderate anxiety for the trial starting in a named quarter, and in exchange locks founding coverage pricing for three years effective at FDA clearance, as one of only three trial-partner plans.
the ask · $15 per engaged member per month upon clearance; the pre-clearance commitment is the signed LOI, not cash
a real yes · A real yes is a signed LOI naming a start quarter and pricing, executed by the medical director or VP of network; conference enthusiasm, 'send us the data when you have it', and unsigned interest from innovation teams are not yes.
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Medical director term-sheet calls
$400 · 14 days
Book 15 calls with behavioral health medical directors from the ACHP directory and consultant introductions. Bring two artifacts: a one-page pivotal-trial design for moderate anxiety (single indication, plan members as trial population) and a one-page coverage-upon-clearance term sheet at $15 per engaged member per month. Ask directly whether they would review the trial-partner LOI.
keep going if · 5 of 15 directors agree in writing to review the trial-partner LOI
2. Priced term-sheet redlines
$600 · 21 days
Send the coverage term sheet to the 5 warmest plans and ask for redlines, not opinions: the PMPM number, the engaged-member definition, the liability clause on autonomous delivery. Have a healthcare attorney review the template once before it goes out. Redlines reveal whether autonomy and price survive contact with a real payer.
keep going if · 3 of 5 plans return redlines that keep autonomous delivery and a PMPM at or above $10
3. One signed dated LOI
$1,500 · 42 days
Fly to the two most engaged plans and negotiate a non-binding trial-partner LOI in person: the plan names a start quarter for member recruitment into the pivotal trial and locks founding pricing effective upon FDA clearance. Counsel finalizes the language. This is the purchase-order equivalent available before clearance.
keep going if · 1 plan signs the LOI with a named start quarter within 6 weeks
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$0
no cash yet: take a signed commitment
how · No money can move: pre-clearance, a health plan cannot buy or pilot an uncleared medical device, so the instrument is a signed trial-partner LOI with a dated start quarter plus an attached coverage term sheet, executed by the plan's behavioral health medical director - the strongest commitment this buyer can legally make today.
what it reserves · One of three trial-partner slots, first access to trial data, and founding pricing of $15 per engaged member per month locked for three years upon clearance
refund · The LOI is non-binding and either party may withdraw in writing at any time before the definitive trial agreement is executed.
target · 1 signed dated LOI and 3 returned term-sheet redlines from 15 medical-director conversations within 6 weeks
before taking money · Until FDA clearance, the team must not market clinical claims or deliver therapy to any patient outside an IRB-approved trial, and every outreach artifact and LOI needs review by FDA regulatory counsel first.
Go: build it if
1 signed LOI with a named start quarter plus 3 of 5 redlines preserving autonomous delivery at $10-plus PMPM: a payer will put its name and members behind this, so the multi-year trial path has a buyer at the end.
Kill: stop if
0 signed LOIs after 15 medical-director conversations, or every redline striking the autonomous-delivery clause or pricing below $8 PMPM: payers will not cover human-out-of-the-loop therapy at viable economics, so do not start a three-year trial.
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
Your behavioral health network likely has weeks-long waits on anxiety referrals while every completed session costs the plan around $150. I'm building autonomous, protocolized CBT for moderate anxiety designed for FDA SaMD clearance, priced near $15 per engaged member per month, and I'm selecting three regional plans as pivotal-trial partners with founding pricing locked at clearance. Would you give me 20 minutes to walk through the trial design and the coverage term sheet?
landing page
Autonomous CBT for anxiety, built for coverage, at one-tenth therapy cost. $15 per engaged member per month upon FDA clearance; three trial-partner slots for regional plans. Request the trial-partner term sheet.
deposit terms
This letter reserves one of three pivotal-trial partner slots: your plan names a start quarter for member recruitment and locks founding pricing of $15 per engaged member per month for three years, effective upon FDA clearance. It is non-binding and costs nothing today, and either party may withdraw in writing at any time before the definitive trial agreement is signed.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
70
Idea Score, 0-100 · raw 43.5 x 1.61
Crowded
competition: more crowded than 75% of ideas · headwind x0.63
+4.5
government priorities, secondary (110 matching grants)
Trend
47
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)51
- Rounds announced 2025+ in the sector38
- Rounds announced 2025+ matching the idea98
- Sector direction (live batch)0
- 2026 trend analyst50
Demand
70
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)60
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain50
100x potential
72
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge100
- Market size axis67
- Moat axis80
- Neighbours still alive38
- Technologist judge50
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were fda-cleared, autonomous, therapy, sold, health, plans, one-tenth, cost.
The idea in full
- What
- Talvia builds a clinically validated conversational AI that delivers protocolized CBT for anxiety and depression as a covered insurance benefit, replacing 150-dollar-per-session human therapy with a 15-dollar-per-member-per-month product. It sells to national health plans and large employer programs through benefits brokers and consultants, and runs clinical operations and safety-monitoring teams alongside the software. The first three-plus years are clinical trials and FDA software-as-a-medical-device clearance; revenue follows the clearance, and the clearance plus payer contracts are the moat.
- Why now
- Whoop's 575M Series G in 2026 shows the scale of consumer spend on health, and the YC X26 batch includes ANORIA (a wearable that reads emotions) and Napkin Math (an AI nutrition coach) - AI coaching for consumers is a wave, but none of these carries clinical clearance, so none can be a reimbursed benefit, which is where behavioral health money actually sits.
- Wedge: first customer and entry point
- Run the pivotal trial on a single indication - moderate anxiety - with one regional health plan as trial partner and first customer, a scope a small founding team with one clinical lead can carry to clearance.
- Path to 100x
- US behavioral health spend is in the tens of billions against a structural therapist shortage, so a 10x cost collapse is the only way supply ever meets demand, and payers are the buyers who capture that saving. The company that clears FDA first and signs national plans owns the covered category for the years it takes anyone else to repeat the trials, which is how a licensing moat compounds into winner-takes-most.
- Ceiling
- Payers may cap per-member pricing aggressively once a second cleared competitor exists, compressing this into a sub-billion contract business.
- Closest real companies, as the generator saw them
- ANORIA and Napkin Math are consumer wellness products with no clinical claims or payer channel; Whoop sells hardware subscriptions to individuals. Talvia competes with human therapist supply, not with any company in the brief.
- Main risk
- A single high-profile safety failure in autonomous mental health AI triggers a regulatory freeze that stalls the category for years.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
5/5
FDA clearance plus national payer contracts in a tens-of-billions behavioral health pool is a compounding license moat with genuine winner-takes-most upside.
Bootstrapper
1/5
Pivotal trials and SaMD clearance before any payer contract is the longest regulatory path on the board.
Operator
3/5
Payers own the budget and feel the $150-per-session cost, but the pivotal trial and SaMD clearance defer revenue past three years.
Technologist
3/5
Pivotal trials and SaMD clearance are a genuine multi-year barrier, but the underlying protocolized CBT chatbot is not itself hard to build.
Risk
2/5
No revenue until FDA SaMD clearance, then a handful of national payers as buyers, with one safety incident able to freeze the category.
trends
3/5
Behavioral health rides the $590M healthcare grant pool, but a Whoop consumer raise is no payer-side shift and FDA-cleared digital CBT predates 2023.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (fda-cleared, autonomous, therapy, sold, health, plans, one-tenth, cost): 67 all-time, 15 from the last two years. Same matching as Idea Check.
Psychotherapy through autonomous and personalized VR-sessions.
Avenda Health offers Unfold AI, an FDA-cleared platform that generates patient-specific 3D cancer maps to aid urologists in planning and executing personalized prostate cancer treatments.
Cambrian Project provides services in Business automation by service robots , AI/IoT technology project & Service/application development.
Your health plan should get better year-round. Not just once a year.
An AI-operated logistics company.
We run benefits, payroll & compliance for startups, for free
Osteoboost is the first and only FDA-cleared, drug-free prescription treatment for low bone density and a platform for a comprehensive solution to osteoporosis.
RNARevive is developing a next-generation RNA platform that enables long-lasting, low-dose protein therapeutics. Our lead candidates tackle the anti-aging and longevity space, targeting osteoporosis, age-related macular degeneration (AMD), and liver diseases.
Superintelligent health insurance that keeps employees healthy
Building the AI functional medicine doctor.
The AI for ER workflows.
Counter Drone Systems. $1.6m sales. We delivered for the DoW.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
33
startup-relevant grants in Consumer
$10M
awarded in the sector, tracked
1
opportunities open now in the sector
- Addressing Rising Mental Health Concerns in Youth: Development of an Digital Evidence-Based App for Providers and Teensawardhigh relevance
NIH / NIMH · SBIR phase I · $314K · posted 2026-09-01
- Personalized Diabetes Management through iPSC-Derived β-cells: A Tailored Approach for Improving Treatment Efficacy in Economically Vulnerable Populationsawardhigh relevance
NIH / NIDDK · SBIR phase I · $307K · posted 2026-08-15
- Accelerating Time-to-Treatment in Rural Areas with a Pre-Hospital EEG Stroke Classification Systemawardhigh relevance
NIH / NIMHD · STTR phase I · $314K · posted 2026-08-05
- SBIR Phase II: AI-Driven Visualization of Rehabilitation Documentation to Support Decision-Making Across Care Settingsawardhigh relevance
National Science Foundation · SBIR Phase II · $1M · posted 2026-07-20
- Developing GLP-1 Producing Genetically Engineered Probiotics for Treatment of Metabolic Diseasesawardhigh relevance
NIH / NIDDK · SBIR phase I · $356K · posted 2026-07-15
- An Internet of Things Automated Cognitive Behavioral Therapy for Insomnia that Improves Cognition in Older Adultsawardhigh relevance
NIH / NIA · SBIR phase I · $500K · posted 2025-09-20
NIH / NIA · STTR phase I · $250K · posted 2026-09-23
NIH / NIA · SBIR phase II · $889K · posted 2026-09-22
Market signal
What the radar sees in Consumer: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Consumer · 182 → 222 → 211 → 156 → 64 new companies 2022 → 2026 · 86% aliveYC F26 live: 4 in this cluster, 3% of the batch (was 3% in S26)Since February, of 782 YC companies here: 6 acquired, 4 shut down, 45 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Software subscription
- Path to 100x
- Collapses a cost 10x
- Market size
- $10-100B market
- Capital intensity
- Capital-medium (ops, field teams)
- Speed to revenue
- R&D first, revenue after 3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Partners and channels
- Moat
- License or regulatory moat
- Geography
- US first
- Regulation
- Heavily regulated
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Consumer and commerce · Consumer
Yearmark
Certified on-device age assurance and minor-safety controls, shipped as one SDK for consumer apps.
Yearmark is a subscription SDK that consumer app companies drop into signup and payment flows to estimate a user's age band on-device from face, voice and interaction signals, then enforce the right minor-safety rules per jurisdiction without sending biometrics to a server.
Consumer and commerce · Consumer
Listwire
One API that lists any secondhand item everywhere and prices it from real comps.
Small resellers and secondhand shops connect once to Listwire and their inventory appears, correctly categorised and priced, across every consumer resale marketplace, with orders, cancellations and payouts flowing back through the same endpoints.
Consumer and commerce · Consumer
Fidara
A licensed AI fiduciary that manages your entire financial life, legally on your side.
Fidara is a consumer AI agent registered as an investment advisor and licensed money transmitter, so it can actually move money, rebalance accounts, refinance debt, contest bills and file the paperwork - not just suggest.
Consumer and commerce · Consumer
Perpetua
A marketplace for persistent AI worlds that remember every player who visits.
Perpetua trains a real-time interactive world model with durable state, so a generated world keeps its geography, characters and consequences between sessions and across different visitors.
Consumer and commerce · Consumer
Castmark
Global marketplace where brands license AI-ready characters, voices and likenesses per use.
Castmark lists characters, voice models and performer likenesses with machine-readable licence terms (territory, media, duration, prohibited uses) and sells them per generation or per campaign to game studios, publishers and consumer brands.
Consumer and commerce · Consumer
Vaultline
Instant marketplace for vaulted collectibles: buy, sell and settle without ever shipping.
Consumers deposit graded cards and sealed hobby product into a partner bonded vault once; after that, ownership transfers instantly on Vaultline's ledger and nothing moves physically until an owner requests withdrawal.
Fictional company written 2026-08-26 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.